CHU AMBROISE PARE   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mons Belgium (1923)

Organization Overview

First Clinical Trial
2000
NCT00006479
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ambroise Paré hospital | AP-HP - Hôpital Ambroise-Paré | C.H.U. AMBROISE PARE AP-HP, Boulogne-Billancourt, France | CMC Ambroise Paré | CMC Ambroise Paré, Neuilly-sur-Seine, France | Department of Anesthesia and Intensive Care - Ambroise Paré Hospital - APHP | Department of Orthopaedics and Traumatology, Ambroise Paré hospital, APHP | Hopital Ambroise Pare | Hospital Ambroise Pare | Hospital Ambroise Pare, Department of Dermatology | Hospital Ambroise Pare Paris | Hospital Ambroise Paré Paris | Infectiology mobile team, Ambroise Paré hospital, APHP | Nadine ATTAL | Orthopaedics, Ambroise Paré hospital, APHP | Orthopedic surgery department, Ambroise Paré hospital, APHP | Orthopédie et traumatologie, Hôpital Ambroise Paré, Boulogne-Billancourt | Pharmacy of Ambroise-Paré hospital, APHP

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Chronic Pain (Phase 3)

Colorectal Neoplasms (Phase 3)

Constipation (Phase 3)

Diabetic Neuropathies (Phase 4)

Ileus (Phase 3)

Inflammation (Phase 3)

Liver Neoplasms (Phase 3)

Melanoma (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Neuralgia (Phase 4)

Neuralgia, Postherpetic (Phase 4)

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 3)

Polyneuropathies (Phase 4)

Rectal Neoplasms (Phase 2)

Shock (Phase 3)

Shock, Cardiogenic (Phase 3)

Warts (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 31